MreB Inhibitor A22

A22 disrupts the actin cytoskeleton of bacteria causing defects in morphology and chromosome segregation.1 It is a competitive inhibitor of ATP binding to MreB and has the ability to disassemble the actin cytoskeleton in bacterial cells.1 It displays antibacterial activity against P. aeruginosa (among many others) including multidrug-resistant clinical isolates and points to MreB as a new target for antibacterial development.2 A22 significantly disrupts biofilm formation by interfering with the ability of bacterial cells to maintain shape and adherence to surfaces.3